Aachal Kotecha
Welwyn Garden City, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 44 publications
Summary of Research: Four-Year Outcomes of Faricimab in Diabetic Macular Edema: Results From the RHONE-X Extension Trial.
Journal: Ophthalmology and therapy
Published: April 15, 2026
Potential 20-week Faricimab Dosing in Wet Age-Related Macular Degeneration.
Journal: Ophthalmology. Retina
Published: July 29, 2025
Potential 20-Week Faricimab Dosing in Wet Age-Related Macular Degeneration.
Journal: Ophthalmology. Retina
Published: July 29, 2025
Outcomes by Faricimab Treatment Interval at Week 48 of TENAYA-LUCERNE Phase III Trials in Neovascular Age-Related Macular Degeneration.
Journal: Ophthalmology. Retina
Published: November 15, 2024
Correction: Infographic: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in neovascular age-related macular degeneration (pooled results from TENAYA and LUCERNE).
Journal: Eye (London, England)
Published: August 26, 2024
Baseline characteristics associated with the first year treatment interval of intravitreal faricimab in neovascular age-related macular degeneration (nAMD).
Journal: BMJ open ophthalmology
Published: July 05, 2024
Infographic: 2-year efficacy, durability and safety of intravitreal faricimab with treat-and-extend dosing up to 16 weeks in neovascular age-related macular degeneration (pooled results from TENAYA and LUCERNE).
Journal: Eye (London, England)
Published: May 31, 2024
Efficacy, durability and safety of faricimab for patients with neovascular age-related macular degeneration: 48-week results from the phase 3 LUCERNE China subpopulation.
Journal: Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
Published: April 19, 2024
Patient Experience Survey of Anti-Vascular Endothelial Growth Factor Treatment for Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema.
Journal: Ophthalmic research
Published: February 14, 2024
Caregiver Experience Survey of Anti-Vascular Endothelial Growth Factor Treatment for Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration.
Journal: Ophthalmic research
Published: February 14, 2024
Infographic: study design of the BALATON and COMINO phase 3 randomised trials of faricimab in patients with retinal vein occlusion.
Journal: Eye (London, England)
Published: December 12, 2023
Last Updated: 09/26/2026